Recursion Pharmaceuticals, Inc. RXRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $74.68M+26.9% | $58.84M+32.0% | $44.58M+11.9% | $39.84M+291% | ||
| $70.95M+56.8% | $45.24M+6.2% | $42.59M-11.8% | $48.28M— | ||
| $3.73M— | —— | $1.99M— | —— | ||
| 5%— | —— | 4.5%— | —— | ||
| $475.27M+51.2% | $314.42M+30.3% | $241.23M+54.9% | $155.7M+15.1% | ||
| $176.59M-0.9% | $178.18M+60.8% | $110.82M+35.8% | $81.6M+41.5% | ||
| $722.81M+34.4% | $537.84M+36.3% | $394.64M+38.2% | $285.57M+48.0% | ||
| -$648.13M-35.3% | -$479.01M-36.8% | -$350.06M-42.5% | -$245.73M-34.4% | ||
| -867.9%-53.8pp | -814.1%-28.8pp | -785.3%-169pp | -616.7%+1,179pp | ||
| $3.24M-77.2% | $14.22M-20.7% | $17.93M+187% | $6.25M+268% | ||
| -$644.89M-38.7% | -$464.79M-39.9% | -$332.13M-38.7% | -$239.48M-28.4% | ||
| —— | -$1.14M+72.1% | -$4.06M— | $0— | ||
| -$644.76M-39.1% | -$463.66M-41.3% | -$328.07M-37.0% | -$239.48M-28.4% | ||
| -863.4%-75.3pp | -788%-52.0pp | -736%-135pp | -601%+1,231pp | ||
| -$1.44+15.3% | -$1.70-8.3% | -$1.57-15.4% | -$1.36+41.1% | ||
| -$564.43M-27.6% | -$442.51M-35.9% | -$325.66M-39.2% | -$233.97M-34.2% | ||
| -755.8%-3.7pp | -752.1%-21.5pp | -730.6%-143pp | -587.2%+1,126pp | ||
| -$648.13M-35.3% | -$479.01M-36.8% | -$350.06M-42.5% | -$245.73M-34.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 7.2% and operating margin is -881.3%, with a -842.9% net margin.
- Where does Recursion Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.